Context Therapeutics (NASDAQ:CNTX) Downgraded by Lifesci Capital to “Hold”

Context Therapeutics (NASDAQ:CNTX) was downgraded by Lifesci Capital from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a research note on Thursday. Finally, Maxim Group decreased their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Stock Performance

NASDAQ CNTX opened at $0.48 on Thursday. The business has a fifty day moving average price of $0.86 and a 200 day moving average price of $1.91. The company has a market cap of $44.47 million, a P/E ratio of -1.01 and a beta of 1.74. Context Therapeutics has a one year low of $0.48 and a one year high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). As a group, sell-side analysts predict that Context Therapeutics will post -0.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Large investors have recently bought and sold shares of the business. Timothy G. Youngquist 2020 Irrevocable Trust acquired a new stake in Context Therapeutics in the second quarter valued at $110,000. BlackRock Inc. acquired a new position in shares of Context Therapeutics during the 2nd quarter worth about $3,417,000. Deutsche Bank AG purchased a new position in shares of Context Therapeutics in the 2nd quarter valued at about $50,000. Bank of New York Mellon Corp acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth about $61,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth about $89,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.